Halozyme (HALO) announced that David Ramsay has been appointed Interim CFO, effective March 23. Ramsay will oversee all financial operations while the company continues its active search for a permanent CFO. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale-up. He previously served as Halozyme’s CFO from 2003 to 2009 and again from 2013 to 2015, during which time the company evolved from a private enterprise to a billion-dollar public biopharmaceutical company.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme price target raised to $94 from $78 at Morgan Stanley
- Halozyme price target raised to $90 from $75 at Benchmark
- Halozyme price target raised to $75 from $65 at Wells Fargo
- Halozyme Earnings Call Highlights Royalty-Fueled Growth
- Halozyme: Strong Royalty Momentum and Underappreciated Multi‑Year Earnings Power Support Buy Rating